Literature DB >> 12570359

Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments.

Raul Gonzalez1, Robert K Heaton, David J Moore, Scott Letendre, Ronald J Ellis, Tanya Wolfson, Thomas Marcotte, Mariana Cherner, Julie Rippeth, Igor Grant.   

Abstract

In recent years, interest in the use of computerized neuropsychological (NP) assessment measures has increased. However, there are limited data regarding how performance on these measures relates to performance on more traditional, clinical instruments. In the present study, 82 HIV+ men, who were all believed on clinical grounds to have neurobehavioral impairment, completed a traditional NP battery (TNB) and the California Computerized Assessment Package (CalCAP, a collection of computerized reaction time tests). Summary scores based on a TNB, as well as those based on the CalCAP, demonstrated significant associations with both degree of immunosuppression (CD4 count) and detectable viral load in cerebrospinal fluid, but not with detectable viral load in plasma. Established norms on the TNB and CalCAP batteries resulted in classifying 57% and 49% of the HIV+ sample as impaired, respectively. When using the TNB as the "gold standard," impairment classifications based on CalCAP summary scores exhibited a sensitivity of 68% and a specificity of 77%. Overall agreement on impairment classifications between batteries was low (kappa = .44). Data from this study suggest that traditional NP batteries and computerized reaction time tests do not measure the same thing, and are not interchangeable in examining HIV-related NP impairments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570359     DOI: 10.1017/s1355617703910071

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  22 in total

Review 1.  An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors.

Authors:  Yin Ting Cheung; Earl Hsien-Jie Tan; Alexandre Chan
Journal:  Support Care Cancer       Date:  2012-04-05       Impact factor: 3.603

2.  Reaction time variability in HIV-positive individuals.

Authors:  Mark L Ettenhofer; Jessica Foley; Nina Behdin; Andrew J Levine; Steven A Castellon; Charles H Hinkin
Journal:  Arch Clin Neuropsychol       Date:  2010-08-26       Impact factor: 2.813

3.  Feasibility and Acceptability of Ecological Momentary Assessment of Daily Functioning Among Older Adults with HIV.

Authors:  Raeanne C Moore; Christopher N Kaufmann; Alexandra S Rooney; David J Moore; Lisa T Eyler; Eric Granholm; Steven Paul Woods; Joel Swendsen; Robert K Heaton; J C Scott; Colin A Depp
Journal:  Am J Geriatr Psychiatry       Date:  2016-12-01       Impact factor: 4.105

Review 4.  Screening for cognitive impairment in human immunodeficiency virus.

Authors:  Victor Valcour; Robert Paul; Stephanie Chiao; Lauren A Wendelken; Bruce Miller
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

5.  Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors.

Authors:  Jane A O'Halloran; Sarah A Cooley; Jeremy F Strain; Anna Boerwinkle; Robert Paul; Rachel M Presti; Beau M Ances
Journal:  AIDS       Date:  2019-07-15       Impact factor: 4.177

Review 6.  Screening for HIV-Associated Neurocognitive Disorders: Sensitivity and Specificity.

Authors:  Reuben N Robbins; Travis M Scott; Hetta Gouse; Thomas D Marcotte; Sean B Rourke
Journal:  Curr Top Behav Neurosci       Date:  2021

7.  Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatment.

Authors:  Stewart M Bond; Mary S Dietrich; Jill Gilbert; E Wesley Ely; James C Jackson; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2016-05-25       Impact factor: 3.603

8.  Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons.

Authors:  Nancy F Crum-Cianflone; David J Moore; Scott Letendre; Mollie Poehlman Roediger; Lynn Eberly; Amy Weintrob; Anuradha Ganesan; Erica Johnson; Raechel Del Rosario; Brian K Agan; Braden R Hale
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

9.  Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings.

Authors:  K Blackstone; D J Moore; D R Franklin; D B Clifford; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; R J Ellis; J H Atkinson; I Grant; R K Heaton
Journal:  Clin Neuropsychol       Date:  2012-06-18       Impact factor: 3.535

10.  Plasma (1 → 3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis.

Authors:  Sara Gianella; Scott L Letendre; Jennifer Iudicello; Donald Franklin; Thaidra Gaufin; Yonglong Zhang; Magali Porrachia; Milenka Vargas-Meneses; Ronald J Ellis; Malcolm Finkelman; Martin Hoenigl
Journal:  J Neurovirol       Date:  2019-07-11       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.